Prostate Cell News Volume 8.24 | Jun 30 2017

TOP STORY

mTORC1-Dependent AMD1 Regulation Sustains Polyamine Metabolism in Prostate Cancer

Scientists showed that mechanistic target of rapamycin complex 1 (mTORC1) regulated polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model and human biopsies of prostate cancer, they identified alterations in tumors affecting the production of decarboxylated S-adenosylmethionine and polyamine synthesis. [Nature] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics

Metabolic and bioorthogonal labeling methods have previously enabled the enrichment and identification of sialoglycoproteins from cultured cells and model organisms. The authors report the first application of this glycoproteomic platform to human tissues cultured ex vivo. [Angew Chem Int Ed Engl] Abstract

Inherited Determinants of Early Recurrent Somatic Mutations in Prostate Cancer

To discover germline events involved in prostate cancer predisposition, the authors developed a computational approach to nominate heritable facilitators of somatic genomic events in the context of androgen receptor signaling. They used a ranking score and benign prostate transcriptomes to identify a non-coding polymorphic regulatory element at 7p14.3 that associates with DNA repair and hormone-regulated transcript levels and with an early recurrent prostate cancer-specific somatic mutation in the Speckle-Type POZ protein gene. [Nat Commun] Full Article

Alternative Splicing Promotes Tumor Aggressiveness and Drug Resistance in African American Prostate Cancer

Scientists identified novel genome-wide, race-specific RNA splicing events as critical drivers of prostate cancer aggressiveness and therapeutic resistance in African American (AA) men. AA-enriched splice variants of PIK3CD, FGFR3, TSC2 and RASGRP2 contributed to greater oncogenic potential compared with corresponding European American-expressing variants. [Nat Commun] Full Article

Inhibition of Androgen Receptor Nuclear Localization and Castration Resistant Prostate Tumor Growth by Pyrroloimidazole-Based Small Molecules

Small molecules capable of inhibiting androgen receptor (AR) nuclear localization could be developed as novel therapeutics for castration resistant prostate cancer (CRPC). Scientists developed a high throughput screen and identified two structurally-related pyrroloimidazoles that could block AR nuclear localization in CRPC cells. [Mol Cancer Ther] Abstract

Expression Analysis of Inflammasome Sensors and Implication of NLRP12 Inflammasome in Prostate Cancer

Using Gene Expression Omnibus public datasets, researchers screened the expression profiles of inflammasome sensors NLRP3, NLRC4, NLRP6, NRLP12, and AIM2 in prostate tumor tissues, and verified their mRNA level in a panel of prostate cancer cell lines. [Sci Rep] Full Article

CRISPR/Cas9 Targeting of GPRC6A Suppresses Prostate Cancer Tumorigenesis in a Human Xenograft Model

Researchers determined whether the K..Y polymorphism is present in human-derived prostate cancer cell lines by sequencing the region of the 3^rd intracellular loop and assessed the cellular localization of a “humanized” mouse GPRC6A containing the K..Y sequence by immunofluorescence. [J Exp Clin Cancer Res] Full Article

Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells

Investigators aimed to evaluate cell-penetrating peptide PepFect 14 as a carrier for delivery of miR-34a-5p into human primary prostate carcinoma-1 (PPC-1) cells. Using microarray expression analysis, they identified a total of 3,283 differentially expressed genes in PF14:miR-34a-5p-transfected cells. [Nucleic Acid Ther] Abstract

CLINICAL RESEARCH

High-Intensity Focused Ultrasound for Radio-recurrent Prostate Cancer: A North American Clinical Trial

Investigators aimed to determine the safety and efficacy of whole-gland high-intensity focused ultrasound in men with radio-recurrent prostate cancer (CaP). 100 men with clinically localized recurrence of CaP at least two years after EBRT received whole-gland HIFU in an open-label trial. [J Urol] Abstract

Dose Considerations for Anti-Cancer Drugs in Metastatic Prostate Cancer

Researchers review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, they discuss the potential for under-exposure of docetaxel and cabazitaxel; over-exposure of enzalutamide; and varied absorption of abiraterone acetate. [Prostate] Abstract

The Stem Cell Factor (SCF)/C-KIT Signaling in Testis and Prostate Cancer

The authors provide an overview of the signaling pathways activated by SCF/c-KIT and discuss the potential application of c-KIT inhibitors for treatment of testicular and prostatic cancers. [J Cell Commun Signal] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Sanpower Group Closes Acquisition of Dendreon

Dendreon Pharmaceuticals LLC announced the close of a transaction in which Sanpower Group acquired Dendreon from an affiliate of Valeant Pharmaceuticals International, Inc. for $819.9 million in cash. By operating as a standalone company, under the ownership of Sanpower Group, Dendreon will strive to further accelerate and expand access to its flagship immunotherapy product PROVENGE^® to prostate cancer patients worldwide. [Dendreon Pharmaceuticals LLC] Press Release

Minomic Clinical Study Progresses for Miltuximab^TM in Prostate, Bladder, and Pancreatic Cancer

Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of Miltuximab^TM, a chimeric version of Minomic’s MIL-38 anti-Glypican 1 antibody conjugated to the radioactive isotope 67Gallium. The MILGa Cancer Imaging Trial is a first-in-human study to evaluate the safety and tumor targeting of Miltuximab^TM in patients with metastatic prostate, bladder, and pancreatic cancer. [Minomic International Ltd] Press Release

GenomeDx Announces New York State CLEP Approval of Decipher Prostate Cancer Tests

GenomeDx Biosciences announced approval by the New York State Clinical Laboratory Evaluation Program of GenomeDx’s prostate cancer classifier tests, Decipher^® Biopsy and Decipher Post-Op, which are genomic tests intended to improve clinical decision-making following biopsy or radical prostatectomy, respectively, in men with prostate cancer. [GenomeDx Biosciences] Press Release

Canada’s Basic Science at Risk of Fading Away, Report Argues

Canada’s scientific enterprise is at risk of sinking to junk bond status as a result of a funding crunch and misguided government and granting council policies, argues a report. In particular, the authors decry a steady shift away from basic science that has left a smaller portion of the nation’s growing scientific community focused on fundamental research. [ScienceInsider] Editorial

Putin Tightens Control over Russian Academy of Sciences

The Russian government has taken further steps to tighten its grip on the Russian Academy of Sciences (RAS) in Moscow. The State Duma—one of the two chambers of the Russian parliament—passed the first draft of a new law that would give president Vladimir Putin the final say in the elections for RAS’s presidency. [ScienceInsider] Editorial

NEW 25^th Biennial Congress of the European Association for Cancer Research (EACR)
June 30-July 3, 2018
Amsterdam, Netherlands

Visit our events page to see a complete list of events in the community.

NEW Academic Position – TRP Channels Screening in Prostate Cancer (Universita’ degli Studi di Torino)

NEW Postdoctoral Position – Prostate Cancer (Cleveland Clinic)

NEW Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Clinical Research Fellow – Prostate Cancer Vaccine Programme (University of Oxford)

Postdoctoral Fellow – Functional Cancer Genomics (Institute of Oncology Research)

Postdoctoral Fellow – Epigenetics and Epigenomics (Cleveland Clinic Lerner Research Institute)

Postdoctoral Fellows – Cancer Research (Institute of Oncology Research)

Postdoctoral Fellow – Prostate Cancer and Head & Neck Cancer (University of Maryland)

Assistant Member – Prostate Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Drug Discovery (The Vancouver Prostate Centre)

Assistant Professor – Prostate Cancer, Carcinogenesis and Chemoprevention, Advanced Tissue Imaging (University of Illinois at Chicago)

Postdoctoral Fellow – Androgen Action in Prostate Cancer (Lerner Research Institute, Cleveland Clinic)

Research Associate – Prostate Cancer (Meharry Medical College)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.